| Patient | Sugar Ray Robinson |
|---|---|
| Date of birth | 1921-05-03 |
| Identifiers | MRN HR-BX003-SYN-TD; SSN (made up) 000-03-9318 |
| Document date | 1984-10-27 |
| Author | Langston Pryce-Okonjo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Sixteen-week review after the sick visit. [S]
Sugar Ray Robinson returns sixteen weeks after intake with his care partner, four weeks after the sick visit for nausea, loose stools and a slow pulse on donepezil 10 mg. Since returning to 5 mg in the morning his stomach has settled, the vivid dreams stopped, and he has not been dizzy. Metformin and lisinopril were restarted after two days. He had the dilated eye examination two weeks ago, with no retinopathy. He goes to the day program twice a week and to the foundation gym once. His care partner is sleeping better with the day program and the caregiver class. [S]
| Element | Detail |
|---|---|
| Donepezil | 5 mg each morning; no side effects |
| Creatinine | 1.0 mg/dL, from 1.2 at the sick visit |
| Eye examination | No diabetic retinopathy |
| PHQ-9 | 3 |
| Care partner | Zarit 16, narrative |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No nausea or diarrhea |
| Cardiovascular | Negative | No dizziness or fainting |
| Neurological | Positive | Memory loss unchanged; no falls |
| Psychiatric | Negative | Mood good; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1,000 mg oral tablet, one tablet twice daily with meals | One tablet twice daily with meals | Oral route | 1982-03-01 | active | S |
| Glipizide 5 mg oral tablet, one tablet before breakfast | One tablet before breakfast | Oral route | 1983-01-15 to 1984-08-18 | completed | S |
| Lisinopril 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1981-06-01 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1982-03-01 | active | S |
| Diphenhydramine 25 mg oral capsule, one at bedtime for sleep, bought over the counter | One capsule at bedtime | Oral route | 1983-10-01 to 1984-07-07 | stopped | S |
| Donepezil 5 mg oral tablet, one tablet at bedtime | One tablet at bedtime | Oral route | 1984-08-18 to 1984-09-22 | completed | S |
| Donepezil 10 mg oral tablet, one tablet at bedtime | One tablet at bedtime | Oral route | 1984-09-22 to 1984-10-01 | stopped | S |
| Donepezil 5 mg oral tablet, one tablet each morning with breakfast | One tablet each morning with breakfast | Oral route | 1984-10-01 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1984-10-27 | Body height | 180 | cm | S |
| 1984-10-27 | Body weight | 75.8 | kg | S |
| 1984-10-27 | Body mass index (BMI) [Ratio] | 23.4 | kg/m2 | S |
| 1984-10-27 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1984-10-27 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1984-10-27 | Heart rate | 66 | /min | S |
| 1984-10-27 | Respiratory rate | 14 | /min | S |
| 1984-10-27 | Body temperature | 36.5 | Cel | S |
| 1984-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1984-10-27 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1984-10-27 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1984-10-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1979)/1.73 sq M | 85 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1984-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 1984-10-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 126/76 seated and 124/74 standing; pulse 66 and regular; weight 75.8 kg |
| Mouth | Moist mucous membranes |
| Mental status | Cheerful and engaged; repeats a story once |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Memory loss over about two years, worse in the past six months, with repeated questions, missed appointments and bills, and getting lost twice while driving in familiar streets, reported by him and his care partner; cause to be found | resolved | confirmed | R41.3 | S — Synthetic presenting problem anchored to his documented Alzheimer's disease; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age. |
| Alzheimer's disease with early onset, confirmed by a positive amyloid PET, with an amnestic presentation; traumatic encephalopathy syndrome, a research diagnosis, considered | active | confirmed | G30.0 | S — Synthetic modern diagnosis by current criteria at the third visit; not a retrospective diagnosis of the historical person beyond the documented Alzheimer's disease. |
| Mild dementia due to Alzheimer's disease (CDR 1, MMSE 22, MoCA 18), without behavioral or psychological symptoms | active | confirmed | F02.A0 | S — Synthetic stage at diagnosis. |
| Type 2 diabetes for about ten years on metformin and glipizide; hemoglobin A1c 6.4%, below his goal, with hypoglycemia risk from the sulfonylurea | active | confirmed | E11.9 | S — Synthetic modern diabetes anchored to his documented diabetes. |
| Hypertension, controlled on lisinopril | active | confirmed | I10 | S — Synthetic modern hypertension anchored to the single press report. |
| Bilateral sensorineural hearing loss, mild to moderate, high frequencies, on audiometry | active | confirmed | H90.3 | S — Synthetic finding checked as a modifiable contributor to cognitive difficulty. |
| Nausea, loose stools, dizziness on standing and a slow pulse (56) nine days after donepezil was raised to 10 mg, with mild dehydration (creatinine 1.2 mg/dL); resolved after returning to 5 mg in the morning and two days of sick-day rules | resolved | confirmed | R11.0 | S — Synthetic adverse effect of a cholinesterase inhibitor; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA, MMSE) | At diagnosis, then yearly, or sooner with change | Up to date | Next in six to twelve months |
| Medication safety | Medicine review for anticholinergic and sedating drugs (Beers) | Every visit | Completed today | No anticholinergic or sedating drugs |
| Survey | Behavioral and psychological symptoms (NPI-Q items) | Every visit | Completed today | None |
| Medication safety | Cholinesterase inhibitor: benefit, nausea, diarrhea, dreams, pulse | Each follow-up and each dose change | Completed today | 5 mg each morning tolerated; pulse 66; 10 mg not tolerated (sick visit) |
| Survey | Depression screen (PHQ-9) | At diagnosis and yearly | Completed today | 3; item 9 scored 0 |
| Self-management | Driving, firearm and home safety | At diagnosis and each follow-up | Completed today | Not driving; no firearm in the home; no wandering |
| Self-management | Care partner support and burden (Zarit, narrative) | At diagnosis, then at least yearly | Completed today | Zarit 16, from 18; day program and caregiver class |
| Laboratory | Hemoglobin A1c, goal under 8.0% for an older adult with cognitive impairment, and hypoglycemia review | Every three months after a therapy change; every six months when stable | Up to date | 6.9% five weeks ago; no low readings |
| Examination | Blood pressure, goal under 130/80 mmHg | Every visit | Completed today | 126/76 mmHg; no standing drop |
| Laboratory | Potassium and creatinine on lisinopril and metformin | Yearly, and after acute illness or dehydration | Completed today | Potassium 4.4 mmol/L, creatinine 1.0 mg/dL (eGFR 85), back to baseline after the dehydration |
| Examination | Dilated diabetic eye examination | Every one to two years without retinopathy | Completed today | Dilated examination two weeks ago: no retinopathy |
| Self-management | Exercise and social activity | Every visit | Completed today | Day program exercise, daily walks and the foundation gym |
Goal progress:
Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026); 13. Older Adults: Standards of Care in Diabetes-2026 (2026); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Practice Parameter update: Evaluation and management of driving risk in dementia (2010); Guiding an Improved Dementia Experience (GUIDE) Model (2024)
Follow-up: Second recombinant zoster dose due two to six months after the first. Review in three months. Call for side effects, falls, low glucose readings or new behavior changes. [S]